MedTrace Logo

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-09-14

No results posted yet for this study

Summary

The purpose of the study is to identify molecular markers at the level of molecular pathway activation to predict efficacy of anti-HER2 therapy with Trastuzumab.

Conditions

Interventions

OTHER

RNA sequencing

Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.

OTHER

Transcriptome analysis

Analysis of RNA-seq data using the Oncobox algorithm.

DRUG

Trastuzumab

Standard Trastuzumab treatment regimen recommended for breast cancer

DRUG

Chemotherapy

Standard chemotherapy regimen recommended for breast cancer

Sponsors & Collaborators

  • Oncobox Ltd., Russia

    collaborator UNKNOWN

  • Vitamed LLC, Russia

    collaborator UNKNOWN

  • Republican Oncological Dispensary of Karelia Republic, Russia

    collaborator UNKNOWN

  • OmicsWay Corp.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2021-04-01
Completion
2022-05-01
FDA Drug
Yes

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03521245 on ClinicalTrials.gov